期刊论文详细信息
Genetics and Molecular Biology
Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
Alícia Dorneles Dornelles2  Louise Lapagesse De Camargo Pinto1  Ana Carolina De Paula1  Carlos Eduardo Steiner1  Charles Marques Lourenço1  Chong Ae Kim1  Dafne Dain Gandelman Horovitz1  Erlane Marques Ribeiro1  Eugênia Ribeiro Valadares1  Isabela Goulart1  Isabel C. Neves De Souza1  João Ivanildo Da Costa Neri1  Luiz Carlos Santana-da-silva1  Luiz Roberto Silva1  Márcia Ribeiro1  Ruy Pires De Oliveira Sobrinho1  Roberto Giuglianiand2  Ida Vanessa Doederlein Schwartz2 
[1] ,Hospital de Clínicas de Porto Alegre Medical Genetics Service Porto Alegre RS ,Brazil
关键词: enzyme replacement therapy;    Laronidase;    Mucopolysaccharidosis Type I;    alph-L-iduronidase;   
DOI  :  10.1590/S1415-47572014000100006
来源: SciELO
PDF
【 摘 要 】

Mucopolysaccharidosis type I (MPS I) is a rare lysosomal disorder caused by deficiency of alph-L-iduronidase. Few clinical trials have assessed the effect of enzyme replacement therapy (ERT) for this condition. We conducted an exploratory, open-label, non-randomized, multicenter cohort study of patients with MPS I. Data were collected from questionnaires completed by attending physicians at the time of diagnosis (T1; n = 34) and at a median time of 2.5 years later (T2; n = 24/34). The 24 patients for whom data were available at T2 were allocated into groups: A, no ERT (9 patients; median age at T1 = 36 months; 6 with severe phenotype); B, on ERT (15 patients; median age at T1 = 33 months; 4 with severe phenotype). For all variables in which there was no between-group difference at baseline, a delta of ;±20% was considered clinically relevant. The following clinically relevant differences were identified in group B in T2: lower rates of mortality and reported hospitalization for respiratory infection; lower frequency of hepatosplenomegaly; increased reported rates of obstructive sleep apnea syndrome and hearing loss; and stabilization of gibbus deformity. These changes could be due to the effect of ERT or of other therapies which have also been found more frequently in group B. Our findings suggest MPS I patients on ERT also receive a better overall care. ERT may have a positive effect on respiratory morbidity and overall mortality in patients with MPS I. Additional studies focusing on these outcomes and on other therapies should be performed.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License

【 预 览 】
附件列表
Files Size Format View
RO202005130148583ZK.pdf 456KB PDF download
  文献评价指标  
  下载次数:15次 浏览次数:9次